San Antonio Breast Cancer Symposium | Conference

Adjuvant T-DM1 Provides Sustained Survival Benefit in HER2+ Early Breast Cancer

December 8th 2023

Adjuvant ado-trastuzumab emtansine continued to improve overall survival and invasive disease-free survival vs trastuzumab after 8.4 years of follow-up in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy enrolled in the phase 3 KATHERINE trial.

SIM0270 Demonstrates Early Antitumor Activity in ER+/HER2– Advanced/Metastatic Breast Cancer

December 8th 2023

The brain-penetrant oral selective estrogen receptor degrader SIM0270 exhibited a favorable safety profile and early signals of antitumor activity in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer, including those with ESR1 mutations.

Ribociclib Plus Nonsteroidal Aromatase Inhibitor Improves iDFS in HR+ HER2- Early Breast Cancer

December 8th 2023

A continued statistically significant improvement in iDFS was observed for patients with HR-positive, HER2-negative early-stage breast cancer who received ribociclib plus a nonsteroidal AI vs a nonsteroidal AI alone, according to the final iDFS analysis of the phase 3 NATALEE trial.

Elacestrant Improves PFS in ESR1-Mutant Metastatic Breast Cancer Subgroups

December 8th 2023

Treatment with elacestrant led to a clinically meaningful improvement in progression-free-survival compared with standard-of-care therapy among patients with estrogen receptor–positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast Cancer

December 7th 2023

Senthil Damodaran, MD, PhD, discusses the efficacy of futibatinib plus fulvestrant in patients with FGFR1-amplified metastatic hormone receptor–positive, HER2-negative breast cancer according to findings from the phase 2 FOENIX-MBC2 trial.

Trastuzumab Deruxtecan Plus Endocrine Therapy Demonstrates Antitumor Activity in HER2-Low/HR+ Metastatic Breast Cancer

December 7th 2023

Anastrozole or fulvestrant plus fam-trastuzumab deruxtecan-nxki demonstrated encouraging antitumor activity in patients with chemotherapy-naïve, HER2-low hormone receptor–positive metastatic breast cancer.

T-DXd Yields Early Activity in HER2+/HER2-Low Breast Cancer With Leptomeningeal Carcinomatosis

December 7th 2023

Treatment with trastuzumab deruxtecan generated clinical responses in patients with HER2-low or HER2-positive advanced breast cancer with pathologically confirmed leptomeningeal carcinomatosis.

Datopotamab Deruxtecan Prolongs PFS in HR+/HER2- Inoperable or Metastatic Breast Cancer

December 7th 2023

Datopotamab deruxtecan resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy among patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.

T-DXd Demonstrates Real-World Efficacy in Advanced Breast Cancer With Dynamic HER2 Expression

December 7th 2023

Administration of fam-trastuzumab deruxtecan significantly prolonged time-to-next treatment in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course.

Disparities in Survival Outcomes Revealed With BluePrint and MammaPrint Subtyping in HR+/HER2– Breast Cancer

December 7th 2023

Precise stratification of hormone receptor–positive, HER2-negative breast cancer using BluePrint and MammaPrint assays revealed comparable 3-year recurrence-free survival rates between Black and White patients despite observed racial differences in the distribution of molecular subtypes.

Freeman on Mortality Differences Across Racial Groups in Male Patients With Breast Cancer

December 6th 2023

Jason Jincong Freeman, discusses mortality differences across various racial groups in male patients with stage I, II, or III breast cancer.

Dr Parsons on the Correlation Between Liquid Biopsy and HER2 Status in Breast Cancer

December 6th 2023

Heather A. Parsons, MD, MPH, discusses the correlation between liquid biopsy and HER2 status in breast cancer, according to data from a novel epigenomic platform.

PFS Benefit Observed With Tucatinib Plus T-DM1 in Previously Treated HER2+ Metastatic Breast Cancer

December 6th 2023

The addition of tucatinib to ado-trastuzumab emtansine (T-DM1) significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer, including those with brain metastases.

Maintenance Pembrolizumab/Olaparib Misses Survival End Points in Locally Advanced or Metastatic TNBC

December 6th 2023

Pembrolizumab plus olaparib did not improve progression-free or overall survival vs pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer who received induction pembrolizumab plus chemotherapy.

BDC-1001 Plus Pertuzumab Is Under Exploration in HER2+ Breast Cancer

December 6th 2023

The phase 2 BBI-20231001 trial evaluating the Boltbody immune-stimulating antibody conjugate BDC-1001 with or without pertuzumab in patients with HER2-positive breast adenocarcinoma is open for enrollment in the United States, France, Italy, and Spain.

Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups

December 6th 2023

The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer enrolled in the phase 3 KEYNOTE-756 trial.

Capivasertib Maintains QOL Benefit Vs Placebo in HR+/HER2– Advanced Breast Cancer

December 6th 2023

Capivasertib plus fulvestrant did not negatively affect quality of life compared with placebo plus fulvestrant in patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer.

AI Assistance Proves Safe, Decreases Time and Cost Burden of Sentinel Lymph Node Detection in Metastatic Breast Cancer

December 6th 2023

Utilizing an artificial intelligence–assisted workflow to detect sentinel lymph node metastases in patients with breast cancer was deemed safe according to current diagnostic standards and reduced the need for immunohistochemistry and its associated financial burden.

Ribociclib Plus Endocrine Therapy Improves PFS and OS in Elderly Patients With HR+/HER2– Breast Cancer

December 6th 2023

The combination of ribociclib and endocrine therapy led to an improvement in progression-free survival and overall survival vs placebo plus endocrine therapy in patients with hormone receptor-positive/HER2-negative advanced breast cancer across all age groups.

Neoadjuvant Platinum Plus Standard Chemotherapy Improves Survival in TNBC

December 10th 2022

The addition of carboplatin to taxane-anthracycline chemotherapy led to a significant improvement in event-free survival and overall survival as neoadjuvant therapy in patients with operable and locally advanced triple-negative breast cancer.